Lilly’s Ramucirumab Makes An Impact In Tough-To-Treat Gastric Cancer, But Will It Be Enough?

The vascular endothelial growth factor inhibitor demonstrated a 1.4 month improvement in overall survival, giving some investors the jitters but encouraging clinician experts, especially given previous targeted drug trial failures.